Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium

Related authors

• Larissa Rossana Souza Stival
• Anelise Medeiros Lago
• Marisa Novaes Falleiro Chaves de Figueiredo
• Ricardo Henrique Goulart Bittar
• Márcia Leite Machado
• João Jorge Nassaralla Junior

Related articles

• Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants
• Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
• Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results
• Gas tamponade followed by laser treatment for macular retinal detachment secondary to optic pit
• Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?
• Anterior lamellar corneoscleral keratoplasty for the management of corneal thinning following treatment with mitomycin-C and interferon to treat highly suspected ocular surface squamous neoplasia: a case report
• Perioperative subconjunctival steroid injection in dropless cataract surgery: a systematic review and meta-analysis
• Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity
• Surgical results regarding the correction of macular hole with and without face-down posturing using 25% SF6 gas: a retrospective case series
• Influence of the dilution method on the intraocular duration of C₃F₈ in vitrectomy for macular hole: a randomized clinical trial

Click here to search